Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma

Leuk Lymphoma. 2022 Dec;63(13):3249-3252. doi: 10.1080/10428194.2022.2115840. Epub 2022 Aug 29.

Authors

Matthew M Lei¹, Erica Tavares¹, Evan Buzgo², Uvette Lou¹, Noopur Raje³, Andrew J Yee³

Affiliations

¹ Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA.
² Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD, USA.
³ Cancer Center, Massachusetts General Hospital, Boston, MA, USA.

PMID: 36036363
DOI: 10.1080/10428194.2022.2115840

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Bone Density Conservation Agents* / adverse effects
Bone Neoplasms*
Denosumab / adverse effects
Diphosphonates / adverse effects
Humans
Hypercalcemia* / diagnosis
Hypercalcemia* / drug therapy
Hypercalcemia* / etiology
Multiple Myeloma* / complications
Multiple Myeloma* / diagnosis
Multiple Myeloma* / drug therapy

Substances

Diphosphonates
Denosumab
Bone Density Conservation Agents